On April 14, 2023 Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), reported that the Company will be represented at two upcoming prestigious scientific conferences (Press release, Bexion, APR 14, 2023, View Source [SID1234630080]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
American Association for Cancer Research Annual Meeting (AACR) (Free AACR Whitepaper) April 14-19, 2023
Orlando, Florida
Bexion is presenting two posters:
Poster 3042 1:30 pm on 4/17/2023 Section 28 Number 14
BXQ-350 May Protect from the Direct Toxicity of Chemotherapeutic Agent leading to Chemotherapy Induced Peripheral Neuropathy
Poster 4437 9:00 am on 4/18/2023 Section 40 Board Number 23
BXQ-350: A Novel Biologic with an Innovative Mechanism of Action Targeting Sphingolipid Metabolism that Induces Cancer Cell Death and Repolarizes the Tumor Environment
12th International Ceramide Conference (ICC) April 16-20, 2023
Charleston, South Carolina
Bexion has been chosen for an oral presentation and two poster sessions. Oral presentation:
Tuesday, April 18 9:10 – 9:30 am Dr. Gilles Tapolsky, Bexion Pharmaceuticals
BXQ-350: Targeting Sphingolipids and Anticancer Activity in Cancer Patients Poster presentations: Posted during meeting
BXQ-350: Modulating Ceramide and Sphingosine-1-Phospate for Anti-Tumor Activity in Cancer Patients with Advanced Disease
BXQ-350: A Novel Biologic that Modulates Sphingolipid Metabolism and Demonstrates Anti-Cancer, Anti-CIPN, and Anti-Viral Properties